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ABSTRACT
We assessed the disease-causing potential of single
nucleotide polymorphisms (SNPs) based on a simple
set of sequence-based features. We focused on SNPs
from the dbSNP database in G-protein-coupled recep-
tors (GPCRs), a large class of important transmem-
brane (TM) proteins. Apart from the location of the
SNP in the protein, we evaluated the predictive
powerofthreemajorclassesoffeaturestodifferentiate
between disease-causing mutations and neutral
changes: (i) properties derived from amino-acid
scales, such as volume and hydrophobicity; (ii)
position-specific phylogenetic features reflecting
evolutionary conservation, such as normalized site
entropy, residue frequency and SIFT score; and (iii)
substitution-matrix scores, such as those derived
fromtheBLOSUM62,GRANTHAMandPHATmatrices.
We validated our approach using a control dataset
consisting of known disease-causing mutations and
neutral variations. Logistic regression analyses indic-
ated that position-specific phylogenetic features that
describetheconservationofanaminoacidataspecific
site are the best discriminators of disease mutations
versusneutralvariations,andintegrationofallourfea-
tures improves discrimination power. Overall, we
identify115SNPsinGPCRsfromdbSNPthatarelikely
to be associated with disease and thus are good can-
didates for genotyping in association studies.
INTRODUCTION
G-protein-coupled receptors (GPCRs) are integral membrane
proteins that include a large family of cell-surface receptors
which are important in signal transduction processes. GPCRs
recognizeawiderangeofextracellularligands,suchasnucleo-
tides, peptides, amines and hormones. GPCRs transduce these
extracellular signals through the interaction with guanine
nucleotide-binding (G) proteins (1,2). This triggers changes
inthelevelsofintracellularmessengers,whichsetoffacascade
ofprocessesaffectingahugerangeofmetabolicfunctions.Not
surprisingly, they are important targets for the majority of
prescription drugs, such as b-blockers for high blood pressure,
b-adrenergic agonists for asthma and anti-histamine (H1 ant-
agonist) for allergy (3,4). The main objective of this paper is to
assess the disease-causing potential of single nucleotide poly-
morphisms (SNPs) in GPCRs from the public database dbSNP
(5). SNPs are single base variations between genomes within a
species.SNPsaredeﬁnedasvariationsthatoccuratafrequency
of at least 1% and are primarily used as markers for genome-
wide mapping and study of disease genes. Additionally, it is
also believed that these small genomic-level differences may
be used to explain the differential drug–response behavior of
individuals toward a drug and can be used to tailor drugs based
on an individual’s genetic makeup (6–8). The tremendous
promise that SNPs hold has spurred a lot of research aimed
atidentifyingSNPs. Thepublication ofthe humangenomeand
the availability of more than 4 million SNPs in the public
database dbSNP provides us with an opportunity to perform
large-scale ‘in silico’ analysis of SNPs.
Given the important roles of GPCRs in many physiological
processes and their pharmaceutical relevance as drug targets,
understanding the role of sequence variations in GPCRs has
potential implications for elucidating disease pathogenesis
mechanisms and drug efﬁcacy issues. To date, there has been
only two published reports of a systematic study of SNPs
in GPCRs (9,10). Small and co-workers (9) studied the vari-
ability in GPCR genes by sequencing 64 GPCR genes in an
ethnically diverse group of 82 individuals. They reported that
variability in GPCR genes were more than that observed
in non-GPCR genes. Additionally, they found that  38% of
SNPs were in transmembrane (TM) regions. Lee et al. (10)
have analyzed coding variations in GPCR genes from various
public sources. In particular, they studied the distribution of
SNPs among the various domains of GPCRs, i.e. transmem-
brane, extracellular and intracellular regions. They found
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doi:10.1093/nar/gki311that disease-causing variations were overrepresented in TM
regions. In contrast, non-disease-causing variations were
underrepresented in TM regions.
With the explosion of data on the human genome and SNP
discovery, it is essential to extract useful information from
this deluge of data. Data mining of the public databases
adds to the pool of useful information about disease genes.
dbSNP has a heterogeneous collection of SNPs obtained by
different methods and the quality of the SNP data is variable.
It has been reported that  40% of SNPs from dbSNP were
absent from a proprietary ‘genecentric’ database leading to the
speculation that some of the SNPs in dbSNP may not be truly
polymorphic (11). Another report estimates that 68% of non-
synonymous SNPs in GPCRs from dbSNP could be false
positives based on the experimental veriﬁcation of a subset
of SNPs in GPCRs (12). Hence, there is a need for some kind
of evaluation of SNPs from public databases to make them
suitable targets for expensive association and genotyping
studies.
While SNPs are widely used as markers, some of these
SNPs may directly explain the pathogenesis of diseases. Non-
synonymous SNPs in coding regions may directly affect the
function of the protein either by disrupting the 3D structure
of the proteins dramatically or by subtle changes resulting in
sub-optimal placement of important residues that affect active
sites, ligand binding, etc. Several groups have studied the
effect of SNPs on protein structure and function using both
sequence and 3D structure-based analyses. Ng and Henikoff
(13,14) have elegantly demonstrated the use of multiple
sequence alignments (MSAs) to identify conserved amino
acid positions that may be critical for protein function.
They rationalized that an amino acid variation occurring in
a conserved position is likely to affect the function of the
protein. They developed an algorithm named SIFT to evaluate
the effect of amino acid changes at any position based only on
the sequence information.
Many other groups have assessed the effect of SNPs in
soluble proteins on the basis of their location in the tertiary
structure of protein. Chasman and Adams (15) predicted that
 30% of nonsynonymous SNPs would affect protein function
based on both sequence and structure-based criteria. Sunyaev
and co-workers (16) estimate that  20% of nonsynonymous
SNPs will have deleterious effects on protein structure based
on the location of SNPs mapped onto 3D structures and com-
parative sequence homology analyses. In a very thorough
study, Wang and Moult (17) developed a set of rules for
predicting the effect of SNPs on protein function based on
the results of in vitro studies of site-directed mutagenesis
experiments in conjunction with data of known disease-
causing mutations in the context of the 3D structures of pro-
teins. They showed that SNPs resulting in deleterious amino
acid changes predominantly affect the stability of proteins.
Liang et al. mapped nonsynonymous SNPs from OMIM
(18,19), a database consisting of human genetic disorders,
on to the structural surfaces of proteins (20). Based on the
geometric location of these structural sites, they showed that
majority of disease-associated SNPs tend to be located in
surface pockets or voids.
Although SNPs in soluble proteins have been evaluated
computationally extensively based on the knowledge of
3D structure of proteins, a PubMed search for SNPs shows
numerousreportsofcodingSNPs(21,22)asmereobservations
andfewattemptstoinfertheireffectonproteinfunction.There
has also been less emphasis on the systematic analysis of SNPs
in membrane proteins by ‘in silico’ methods owing to the
paucity of 3D structures for membrane proteins.
Mutations that are lethal to an organism are never observed.
Fatal mutations are extremely low frequency changes and are
by deﬁnition notincludedaspolymorphisms.Itisbelieved that
there are common variants that contribute to disease (23). The
goal of this study is therefore to correlate such SNPs and their
potential to cause disease. It should be noted that correlating
SNPs to a disease state is a very complex problem, and the
in silico studies that have been discussed above are applicable
only to monogenic disorders. The pathogenesis of many dis-
eases has a very complex underlying mechanism involving
several genes and pathways. Also, several SNPs that are
mildly deleterious to a protein in isolation can be very dele-
terious to an organism when certain combinations of such
SNPs occur together.
GPCRs contain seven transmembrane regions separated
by six loops: three extracellular and three intracellular, an
extracellular N-terminus and an intracellular C-terminus.
Several groups have attempted to model the tertiary structure
of a GPCR of their interest based on the crystal structure
of rhodopsin, the only available 3D structure for a GPCR
(24–27). However, we have adopted a different approach
in order to make it applicable to all membrane proteins.
Given that there are very few high resolution 3D structures
for membrane proteins, a general approach that will be applic-
able to all membrane proteins should be based on criteria
independent of 3D structural information for the proteins.
Moreover, the modeling of GPCRs based on rhodopsin itself
presents some problems (28). Therefore, we have analyzed the
SNPs in GPCRs from dbSNP primarily based on the properties
of amino acids and the sequence-based tool SIFT to dis-
tinguish between disease-causing substitutions and neutral
substitutions.
As 3D structural information is not available for most
proteins, researchers have used several sequence-based and
phylogenetic features to study the effect of amino acid vari-
ations on protein structure and function (16,29–37). These
features are described in Table 1. Cai et al. (29) used several
amino acid properties as features in their Bayesian approach
for predicting pathogenic mutations. Of the several physico-
chemical properties of amino acids, they found that change in
hydrophobicity was the only amino acid-based property that
had a predictive value in conjunction with positional entropy.
They also found that change in residue frequency was a
good predictor in differentiating deleterious versus benign
mutations. Saunders and Baker (36) used structural and
evolutionary information to predict deleterious mutations.
They clearly showed that a combination of just two features,
SIFT score (a residue conservation index) and a solvent-
accessibility term, were enough to differentiate between
deleterious and neutral variations (13). Several studies have
shown that substitutions at evolutionarily conserved sites are
deleterious to the proteins (Table 1). Ferrer-Costa et al. (30)
demonstrated that deleterious mutations are associated with
extreme changes in sequence and structure-based features
that relate to protein stability. Based on these results, we
have included three major classes of features to study the
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(i) Propertiesbasedonaminoacidscale.Weusedchangesin
volume and hydrophobicity as simple physicochemical
features describing an amino acid. In addition, we used
anadditionalhydrophobicityfeature,GEShydrophobicity
scale, for TM regions, because it was specifically devel-
oped for helical TM regions and was shown to be better
than several other hydrophobicity scales for TM helix
prediction (38).
(ii) Position-specific phylogenetic features. We used SIFT
scores, normalized site entropy and change in residue fre-
quency at a given position as additional features. These
features are calculated from MSAs.
(iii) Substitution matrix scores. We used BLOSUM62,
GRANTHAM and PHAT substitution scores to assess
amino acid changes and their potential to be deleterious
to the protein. These are phylogenetic features that are not
position-specific.
MATERIALS AND METHODS
Mapping SNPs on to GPCRs
SNPs from build 110 of dbSNP were used for this ana-
lysis. Sequences containing SNPs were downloaded from
ftp://ftp.ncbi.nih.gov/snp/human. Homology matches to
GPCRs were obtained by performing a six-frame translational
BLAST (39) search of the sequences containing SNPs from
dbSNP against the GPCRDB database (release 8) downloaded
from www.gpcr.org (40,41). Matches which were at least
18 amino acids long with E-values <10
 4 were considered
as signiﬁcant matches and for a given query sequence,
the most signiﬁcant match (i.e. the match with the smallest
E-value) was chosen. Since the average length of a transmem-
brane helix is between 21 and 22 amino acids with a large
variation around the mean (42,43), we used 18 amino acids
as the minimum match length. Once the query sequences
containing the SNPs were mapped on to GPCR proteins,
sequences containing SNPs that lead to a change in amino
acid, nonsynonymous SNPs, were extracted. At this stage,
all matches to olfactory GPCR proteins were removed as it
is known that nonsynonymous changes in olfactory receptors
are predominantly owing to positive selection for a diverse
olfactory repertoire (44,45). In addition,  60% of the com-
plete olfactory subgenome are pseudogenes (46,47).
Domain information
The locations of nonsynonymous SNPs in the various
domains (transmembrane, intracellular and extracellular) of
the 7-TM GPCR proteins were elucidated based on the
annotations from GPCRDB. In GPCRDB, TM helices were
Table 1. This table summarizes the different sequence-based features that have been used for identifying amino acid substitutions that could be deleterious to the
protein and the results obtained from these studies
Sequence-based features Comment Reference
Properties based on amino acid scale
Mass, volume, surface area, side-chain
properties (charge, polarity), partial
specific volume, hydrophobicity,
alpha helix propensity, relative
occurrence, percent buried, pKa.
The physicochemical properties were used as features in a Bayesian framework
to predict the pathogenecity of an amino acid variation. Change in hydrophobicity
coupled with low positional entropy was shown to be a good predictor.
(29)
Position-specific phylogenetic features
Positional entropy, modified Shannon
entropy and normalized site entropy
Substitutions at evolutionarily conserved sites have been shown to be strongly
correlated with disease-causing mutations. Conservation at a position in a
protein sequence has been assessed using slightly modified versions of
sequence entropy from MSAs.
(29,30,33–36)
Change in residue frequency Residue frequency at a given amino acid position was calculated for both variants from
multiple-sequence alignments. Change in residue frequency in conjunction with
hydrophobicity correlated with the observed phenotype.
(29)
Conservation related to allele
frequency
Absolutely conserved residues between at least three mammalian orthologs were identified
and variations at these positions were shown to be underrepresented at high allele
frequencies compared to variations at unconserved sites.
(31)
Degree of conservation using
tree method
Thenumberofsubstitutionsatagivenpositioninasequencewasestimatedbasedonknown
phylogenetic relationships between species. Disease-associated mutations were more
prevalent at conserved sites.
(32)
SIFT Calculates a conservation index based on MSA. Normalized probabilities for all possible
substitutionsat a givenamino acid position are obtained from the MSAand substitutions
with probabilities below a certain cutoff are deemed intolerant to the protein.
(13,14)
Substitution matrices
BLOSUM, PAM and GRANTHAM It was shown that  40% of disease-causing changes had highly unfavorable
BLOSUM62 scores. Similar general trends were seen for PAM matrix scores (30).
(13,30–32,36)
A clear correlation between BLOSUM62 and allele frequency of nonsynonymous
SNPs was not seen in a study of SNPs in membrane-transporter genes (31).
BLOSUM62 scores were able to distinguish tolerant from intolerant substitutions in
a variety of proteins with total prediction accuracies ranging from 47 to 70% (13).
About 40% balanced classification error was reported by Saunders et al. (36) using
BLOSUM62 scores as a predictive feature.
Miller et al. (32) showed that disease-causing amino acid changes are more radical
than variation found among species using GRANTHAM scores.
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adjusted based on MSAs because it is hypothesized that
the TMs must be aligned and of the same lengths for all
the members of a receptor family/subfamily. The ends of
Class A helices were determined from the alignment with
bovine rhodopsin.
Validation datasets
Two control datasets were used to benchmark the predictive
power of the sequence-based features to predict the disease-
causing potential of an SNP.
Dataset containing disease mutations. Mutations in GPCRs
that are associated with disease were compiled from SWISS-
PROT (version 40.44) (49,50). All proteins containing disease
mutations were extracted from SWISS-PROT. This list was
cross-referenced with the protein IDs from GPCRDB to obtain
disease-associated mutations in GPCRs.
Dataset consisting of neutral variations. For a dataset of
neutral variations, homologs to all the GPCR proteins associ-
ated with disease were directly extracted using the multiple
alignment ﬁles from GPCRDB. Amino acid variations
between sequences >95% identical were considered as neutral
variations similar to the approach used by Bork et al. (16). The
logic behind this assumption is that variations in highly homo-
logous sequences between species are generally neutral and
are highly unlikely to be deleterious because deleterious
changes will be selectively removed during the course of
evolution. Nevertheless, it should be pointed out that in
some instances, some of these changes may be functional
changes important in one species, but notin the other. Paralogs
with different functions could have high sequence similarity to
homologs. To ensure that we do not include such functional
variations as neutral changes in this dataset, we removed
all paralogous homologs. This was accomplished in the
following manner:
(i) All homologs to the control dataset proteins containing
disease mutations with >95% sequence identity were
extracted from GPCRDB.
(ii) For each target disease protein, only one ortholog was
chosen from each species based on the best match to the
targetprotein.Thesequencewithhigherpercentidentityto
the target protein was chosen as the best match.
Distribution of mutations among the three domains
of GPCRs
The partitioning of the mutations in the different datasets (the
validation datasets and the dbSNP dataset) among the various
domains of the GPCRs was assessed assuming a Poisson pro-
cess to check whether the mutations within any dataset are
distributed randomly in the transmembrane, intra and extra-
cellular regions of the GPCRs. For example, in the case of the
dataset containing the disease mutations, the occurrence of
disease mutations in the three domains were modeled to ﬁt
a Poisson distribution using the following equation:
Py ðÞ¼
mye m
y!
‚
where m is the expected average number of disease mutations
in a given domain obtained based on the density of disease
mutations, y = 0, 1, 2,..., P(y) is the probability of random
occurrences of ‘y’ number of disease mutations in that domain.
The null hypothesis that we are testing is that disease muta-
tions are randomly distributed in TM, extracellular and intra-
cellular regions. Similar analyses were performed on the
neutral variations and the SNP dataset.
For the dataset containing disease mutations, the average
number of mutations in TM regions is calculated as follows:
m ¼ Total number of amino acids comprising
TMs in the disease proteins · density of mutations‚
where,
Density of mutations
¼
Total number of disease mutations
Total number of amino acids in the disease proteins
:
When the observed number of mutations is greater than the
expected average number of mutations, we assessed the sig-
niﬁcance of this difference by calculating the sum of P(y)
values for all values >y, where y is the observed number
of mutations. Similarly, when the observed number of muta-
tions is smaller than the expected average number of muta-
tions, we calculated a cumulative P-value by adding P(y)
values for all values <y. A small P-value (P < 0.05) indicates
that the occurrence of ‘y’ number of mutations in a domain is
not random.
Free energy changes
The changes in free energy of hydropathy, DDG, owing to
amino acid variations in transmembrane regions were evalu-
ated using the GES hydrophobicity scale (38) as follows:
DDG ¼ DGvariant   DGwild-type
Here, DG refers to the transfer free energy of an amino acid
from water to membrane. The various subscript notations on
the right-hand side of the equations refer to the following:
(i) For the dataset pertaining to disease mutations, DGvariant
refers to the free energy value pertaining to amino acid
causing disease and DGwild-type refers to the free energy
value of the amino acid in the native protein.
(ii) For neutral variations, ‘variant’ refers to the neutral
variation and ‘wild-type’ refers to the amino acid at that
position in the native protein. For the SNPs from
dbSNP,‘variant’referstothealteredaminoacidasaresult
of an SNP.
Allele frequency information is not available for all vari-
ants in dbSNP. Therefore, for SNPs from dbSNP, the identity
of the wild-type amino acid for a protein of interest was
obtained directly from the amino acid sequence in GPCRDB
and the other amino acid was designated as the ‘variant’
amino acid. In cases where both SNPs translated the codons
to two different amino acids that differed from wild-type,
they were considered as two variant amino acids and calcu-
lations were performed with respect to the wild-type amino
acid from the parent sequence in GPCRDB. The absolute
value of the free energy changes were used in the logistic
regression analysis.
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For the volume calculations, changes in volumes, DV, were
calculated. For this analysis, average residue volumes listed in
Gerstein et al. (51) were used. These volumes were calculated
according to the Richards’s implementation of Voronoi
method based on 118 structures from the PDB. The absolute
value of the volume changes were used in the logistic regres-
sion analysis.
SIFT analysis
SIFTversion2.0wasusedfortheanalyses(13,14).Thedefault
settings were used for executing SIFT. The proteins of interest
were queried against SWISS-PROT (version 40.44) to extract
sequences homologous to the query protein. The MSA
sequence alignment used for calculating the conservation
index was automatically generated by SIFT.
Change in hydrophobicity
Changes in hydrophobicity between two variants at a given
amino acid position were evaluated using the Kyte Doolittle
hydrophobicity scale (52). We calculated change in hydro-
phobicity using the same formalism that was used for change
in free energy of hydropathy. Change in hydrophobicity as
well as the absolute value of the hydrophobicity change were
usedintheinitialstagesoflogistic regressionanalysis.Change
in hydrophobicity was found to be a weak predictive feature
and the absolute value of hydrophobicity difference performed
better. Therefore, we only used the absolute value of hydro-
phobicity difference as a predictive feature for the various
logistic regression analyses. The magnitude of change in
hydrophobicity gives an estimate of how well the hydrophobic
nature of a residue is conserved.
Normalized site entropy
Normalized site entropy for all the amino acid positions in the
MSA was calculated using the software program AL2CO (53).
The site entropy was calculated based on the entropy-based
measure given as follows:
Ce i ðÞ¼
X 20
a¼1
f a i ðÞ ln f a i ðÞ
where C
e(i) is the entropy with the reverse sign at position i,
fa(i) represents frequency of amino acid ‘a’a tith position
obtained from MSA generated by SIFT. The amino acid fre-
quencies were estimated using an independent-count-based
weighting scheme in order to correct for the masking effect
of highly similar sequences over fewer divergent sequences in
a MSA (54). The normalized site entropy was calculated by
subtracting the mean site entropy from the site entropy and
dividing by the standard deviation.
Change in residue frequency
The amino acid frequencies of the two amino acid variants at a
given position were calculated directly from the alignments
generated by SIFT. The change in residue frequency at a
position was calculated using the same general formalism
outlined above for the control datasets (disease and neutral)
and the dbSNP dataset. The absolute value of change in res-
idue frequency was used for the logistic regression analysis.
Logistic regression analysis
Logistic regression was used to discriminate disease-causing
mutations from neutral ones. In the logistic regression model,
the probability that a mutation is disease-causing is related
to the weighted linear combination of scores for individual
features in the following way:
log
p
1 p
¼ w0 þ
X M
j¼1
wjsj 1
where p is the probability that the mutation is disease-causing,
and sj is the score of the jth feature for this mutation. To
estimate the weights w0, w1,..., wM, a training set of N muta-
tions is used where each mutation is known to be disease-
causing or neutral. From the training set, the likelihood func-
tion, i.e. the probability of observing the data given the
weights, is computed in the following way:
Lw 0‚w1‚ ...‚wM ðÞ ¼
Y N
i¼1
Li ¼
Y N
i¼1
p
yi
i 1 pi ðÞ
1 yi 2
where for the ith mutation, pi is the probability that the muta-
tion is diseasing-causing, computed from Equation 1. yi, the
response variable, is equal to 1 if the ith mutation is disease-
causing, and 0 if otherwise. Li, the likelihood of the logistic
regression model given the ith mutation in the training set, is
equal to pi if the mutation is disease-causing, and 1   pi if the
mutation is neutral. Finally, the weights w0, w1,..., wM are
chosen such that the likelihood function L(w0, w1,..., wM)i n
Equation 2 is maximized.
Logistic regression analysis was performed using the Weka
machine learning workbench (55). Error rates were calculated
with 10-fold cross-validation.
RESULTS
Nonsynonymous SNPs in GPCRs, from the public database
dbSNP, have been evaluated by ‘in silico’ methods in order to
assess their pathogenic potential. Speciﬁcally, the effect of
amino acid changes at a given position in a GPCR has been
assessed usingsimplephysicochemicalindices ofamino acids,
position-speciﬁc phylogenetic features and substitution matrix
scores. We used a dataset consisting of disease mutations
and another comprising neutral variations in a set of GPCR
proteins, as a training dataset in a logistic regression analysis
to classify them as disease-causing and neutral variations.
A correct prediction of  89% accuracy was obtained using
a combination of all features. The model obtained from this
training dataset was used to predict the pathogenecity of SNPs
in GPCRs from dbSNP by logistic regression. A list of SNPs in
GPCRs from dbSNP that would potentially affect the function
of the proteins has been obtained using this methodology. The
observed correlations of SNPs with the various features are
discussed below.
Location of the amino acid variations
Of the 284 disease-causing mutations, 164 are found in trans-
membrane regions. Assuming that the mutations are distrib-
uted according to a Poisson process, the disease-causing
changes are highly overrepresented in transmembrane regions
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Lee et al. (10) who used a different set of disease mutations.
Among the mutations in the disease dataset, mutations in the
extracellular and intracellular domains are underrepresented.
This may imply that changes in TM regions are disease-
causing presumably because such changes may directly affect
either the structure or function of the receptor. Mutations in
TM regions could abrogate or diminish the activity of the
protein when a ligand-binding site is affected. On the other
hand, a mutation in a TM region could compromise the pro-
tein’s structural integrity owing to its effect on helix–helix
packing interactions. Similar analyses of the dataset compris-
ing neutral variations show a different trend. Here, the occur-
rence of neutral variations in the TM and extracellular regions
appears to be random, whereas neutral variations are under-
represented in the intracellular regions. The SNPs in dbSNP
are signiﬁcantly underrepresented in TM regions and overrep-
resented in extracellular regions. The crude analysis at this
level indicates that most of the SNPs in dbSNP are similar to
neutral variations and are probably benign substitutions.
Distribution of scores based on different substitution
matrices
The nature of amino acid changes were assessed in terms
of scores using various substitution matrices. We used the
BLOSUM62, GRANTHAM and PHAT substitution matrices.
BLOSUM62 is a widely used robust substitution matrix (56).
We also used GRANTHAM D values to evaluate the amino
acid changes. In order to alleviate concerns about the suitab-
ility of BLOSUM matrices derived from a database of soluble
proteins to TM proteins, we used the PHAT matrix for TM
regions (57).
(i) BLOSUM62 matrix: We assigned BLOSUM62 scores to
thevariationsinallthreedatasets.Figure1aisahistogram
showing the distribution of BLOSUM62 scores for the
disease, neutral and dbSNP variations. The distribution
of scores for the disease and neutral variations is signifi-
cantly different (c
2 = 141.07, P < 0.001, 6 degrees of free-
dom). A total of 44.7% of disease-causing mutations have
scores < 1, whereas only 9.7% of neutral changes have
scores < 1. Forscores>1, only2.8%are disease-causing,
whereas 30.2% are neutral. For scores between  1 and 1,
thereisnowaytodiscriminatebetweenthetwosets.Thus,
extreme values of BLOSUM62 scores can be used to
discriminate between disease-causing and neutral varia-
tions. Analyses of mutations in soluble proteins have
yielded similar results (30). The correlation between
BLOSUM62 scores and the deleterious nature of an
amino acid substitution has been seen in some cases and
not in others (13,30–32,36). For GPCRs, BLOSUM62
scores seem to be a fairly good predictor of deleterious
substitutions.Itisnotobviouswhythisisthecase.Itisclear
fromFigure1athatthedistributionsfortheneutralandthe
dbSNP variations are extremely similar.
(ii) GRANTHAM matrix: GRANTHAM scores >100 are con-
sidered radical changes. Figure 1b depicts the distribution
ofGRANTHAMscores.ThedistributionofGRANTHAM
scores for the disease and neutral variations are different
(c
2 = 91.2, P < 0.001, 8 degrees of freedom). Variations
withscores>100are increasinglyassociatedwith disease-
causing mutations. However, the distinction between
disease-causing and neutral mutations is not as clear-cut
as the BLOSUM62 results.
(iii) PHAT matrix: It has been previously reported that
BLOSUM62scorescouldnotbeusedtodiscriminatedele-
terious mutations from benign changes in human mem-
brane transporter genes (31). This could be owing to
the fact that BLOSUM62 scores are derived primarily
from soluble globular proteins. In the case of GPCRs,
BLOSUM62 does seem to be a fairly good discriminator
betweendisease-causingandneutralvariations.Neverthe-
less, the variations in TM regions were assessed with
PHAT, a transmembrane-specific substitution matrix.
From Supplementary Figure 1S, it is very clear that
PHAT scores < 1 are predominantly associated with
disease-causing mutations. The distributions of PHAT
scores for disease-causing and neutral changes in TM
regions are significantly different (c
2 = 100.73,
P<0.001,14degreesoffreedom).While64.6%ofdisease
mutations have PHAT scores < 1, only 5.6% of neutral
variations have PHAT scores < 1. Thus, PHAT substitu-
tion scores < 1 is a very good discriminator for disease-
causing and neutral variations in TM regions. A similar
analysis of BLOSUM62 scores of amino acid changes in
transmembrane regions shows that only 46% of disease
mutations and 7.9% of neutral changes have BLOSUM62
scores < 1. This is depicted in Supplementary Figure 1S.
Thus,PHATscoresarealsoagooddiscriminatorofdisease
versus neutral amino acid changes in transmembrane
regions similar to BLOSUM62 scores. Interestingly,
logistic regression analysis (see Table 4) indicates that
BLOSUM62performssomewhatbetterthanPHATscores
in TM regions.
Free energy change of hydropathy associated with
amino acid replacements in TM regions
Free energy changes associated with variations in TM regions
were evaluated using the transfer free energies based on the
Table 2. Distribution of the various amino acid changes among the TM, extracellular and intracellular regions for the disease-causing, neutral variations and
SNPs from dbSNP
Domain Disease Neutral dbSNP
Transmembrane 164 (93) P = 1.9 · 10
 11 90 (86) P = 0.35 112 (158) P = 2.2 · 10
 5
Extracellular 80 (111) P = 0.001 96 (82) P = 0.06 200 (159) P = 0.0009
Intracellular 40 (80) P = 5.5 · 10
 7 61 (79) P = 0.019 152 (126) P = 0.056
The numbers in the parentheses is the expected number based on a Poisson distribution and the numbers left of the parentheses indicate the observed number of
variations in the corresponding domain.
Nucleic Acids Research, 2005, Vol. 33, No. 5 1715GES hydrophobicity scale. Supplementary Figure 2S shows
the frequency distribution of variations as a function of
change in free energy of hydropathy. The change in free
energy of hydropathy owing to neutral variations is small,
varying predominantly between 0 and 2 kcal/mol. However,
a substantial number of disease-causing variations also have
similar destabilizing/stabilizing free energy changes. There-
fore, small changes in free energy values do not allow the
classiﬁcation of an amino acid variation as either neutral or
disease-causing. Substitutions that are highly destabilizing
(>8 kcal/mol) are always associated with disease-causing vari-
ations, as seen in Supplementary Figure 2S. Overall, the
dbSNPs in GPCR proteins have a similar distribution as
neutral variations.
Change in side-chain volumes
The changes in the volume occupied by different side-chains
were evaluated to see whether there was any correlation to
disease-causing mutations versus neutral variations. Logistic
regression analysis indicates that absolute volume change has
a modest predictive value in differentiating between disease-
causing and neutral variations (data shown in Table 4).
Change in hydrophobicity
The changes in hydrophobicity accompanying the substitution
of one amino acid by another were evaluated to see whether
it would be a useful feature to distinguish between disease-
causing and neutral variations. Logistic regression analysis
indicates that change in hydrophobicity also has a modest
predictive value in differentiating between disease-causing
and neutral variations (data shown in Table 4).
Change in residue frequency
The amino acid frequencies of the two amino acid variants at a
given position were calculated directly from the alignments
generated by SIFT. Figure 2 shows the histogram of change
in residue frequency for the two benchmark datasets and
the dbSNP dataset. When the ‘change in residue frequency’
is small (values close to 0), the amino acid variations corres-
ponding to these values tend to be neutral variations. In con-
trast, a large portion of disease-causing mutations are
associated with big values of ‘change in residue frequency’.
This distribution shows that SNPs in dbSNP are more similar
to neutral SNPs than disease-causing mutations.
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Figure 1. (a) Histogram of BLOSUM62 scores. (b) Histogram of GRANTHAM scores. Here, the black bars represent disease variations, white bars indicate
neutral variations and the shaded bars are dbSNP variations.
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While all the above features used to evaluate amino acid
variations are based on simple physicochemical parameters,
we also analyzed the relationship between sequence conser-
vation and the effect of variations in highly conserved posi-
tions using SIFT. Ng and Henikoff (13,14) have developed a
tool called SIFT to identify conserved positions that may be
critical for protein function using MSA.
SIFT scores were used to assess the two control datasets,
disease-causing and neutral variations in GPCRs, Of the 284
disease-causingmutations, SIFT predicted 213mutations tobe
deleterious. Thus, SIFT correctly identiﬁed 75% of disease-
causing mutations as intolerant substitutions. In the case of
neutral variations, the performance of SIFT was even better.
SIFT predicts 94% of neutral variations to be tolerant substi-
tutions. SIFT did not score 1 disease mutation and 3 neutral
variations. SIFT was used to assess the dbSNPs in GPCRs.
Based on SIFT scores, 74.8% of SNPs in GPCRs from the
dbSNP database are neutral variations. Thus, only 25.2% of
SNPs are predicted to be deleterious substitutions.
Normalized site entropy
Figure 3 shows the distribution of normalized site entropy
scores for disease mutations, neutral variations and SNPs in
dbSNP. Clearly, the distribution of disease-causing mutations
is different from neutral variations. Neutral variations are
associated with a peak at a normalized site entropy value
of  1, whereas the normalized site entropy values associated
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Figure 2. Histogramofchangeinresiduefrequencyforthedisease-causing,neutralanddbSNPvariationdatasets.Theabsolutevalueofchangeinresiduefrequency
is shown. The black bars represent disease variations, white bars indicate neutral variations and the shaded bars are dbSNP variations.
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Figure 3. Frequency distribution of normalized site entropy values for the disease-causing, neutral and dbSNP variation datasets. The black bars represent disease
variations, white bars indicate neutral variations and the shaded bars are dbSNP variations.
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of which are >0.25. As with most other features described so
far,the distributionofSNPs indbSNPis very similar to neutral
variations.
Logistic regression analysis
It is clear that it is possible to use some of the above features to
predictwhetheraSNPwouldbedeleteriousorneutral.Logistic
regression analysis was performed to elucidate the best pre-
dictorsandtherelativecontributionsofthedifferentfeaturesto
a prediction. Logistic regression is a better alternative to linear
regressionwhentheresponsevariableisdichotomous,whichis
true in our case: a mutation can be either disease-causing or
neutral. We performed logistic regression analysis in several
different ways. As the TM regions have more predictive
features, the logistic regression was performed in two ways:
(i) analysis of a dataset comprising all variations (TM and non-
TM);and (ii) analysis of two datasets obtainedby grouping the
variations into TM and non-TM datasets.
In the ﬁrst model, all variations were analyzed using the
following features: BLOSUM, GRANTHAM, volume and
hydrophobicity changes, location of the variation (TM or
non-TM), SIFT scores, normalized site entropy and change
in residue frequency. In the second model, variations in TM
regions and non-TM regions were divided into two groups.For
TM regions, two additional features were used: PHAT scores
and change in free energy of hydropathy. The results of the
logistic regression analyses are discussed below.
Table 3 shows the results obtained from a logistic regression
analysis of all variations (disease and neutral changes) using
only the features common to both TM and non-TM regions. It
can be seen that the overall error rate drops from 18.41 to
11.20% when SIFT is complemented with other features. To
assess the predictive power of each feature, logistic regression
analyses were performed using each feature individually for
the classiﬁcation. The total error rates obtained from this ana-
lysis are shown in Table 4. The error rates are reported for the
analysis on the training dataset including all variations (TM
andnonTM)inallcases,exceptforthelastthreefeaturesinthe
row (PHAT, BLOSUM62 and change in free energy of hydro-
pathy). For those three features, the error rates are reported
for the dataset comprising variations only in the TM regions.
It is clear from Table 4 that the top three best discriminators
of disease versus neutral variations are the position-speciﬁc
phylogenetic features that describe evolutionary conservation.
Allthreefeatures,change inresidue frequency,SIFTscoreand
normalized site entropy, have individual prediction error rates
 18–20%. In the absence of these three features, the error rate
is 26.38%. The error rate drops to 11.95% when the three
position-speciﬁc phylogenetic features are used together for
the logistic regression analysis. The addition of other features
lowers the error rate even further to 11.20%.
Tables 5 and 6 summarize the results obtained from a
logistic regression analysis of the variations in the control
datasets sub-groupedintotwosets:oneconsistingofvariations
only in TM domains and the other comprising variations
in non-TM domains. For variations in non-TM regions, the
error rate was almost twice that of the error rate in TM regions
(Table 6). It is seen that predictions for the TM regions are
more accurate than the non-TM regions. In all the cases, the
combination of all three position-speciﬁc phylogenetic fea-
tures, SIFT score, normalized site entropy and change in res-
idue frequency, signiﬁcantly improves the overall prediction
accuracy. This underscores the importance of position-speciﬁc
phylogenetic features in the assessment of disease-causing
potential of an amino acid substitution at a particular site in
a protein.
It is clear from Tables 3–6 that in all the cases the position-
speciﬁc phylogenetic features perform the best. On the other
hand, in the absence of the phylogenetic features, the other
features can still be used with a prediction accuracy of  70%.
Logistic regression was also performed to classify all the
variations as disease-causing or neutral using each phylogen-
etic feature individually. The prediction error rates for this
analysis are shown in Table 7. Of the three phylogenetic fea-
tures, SIFT scores perform better in TM regions than in non-
TM regions. For the other two features, their predictive power
is not signiﬁcantly different for TM versus non-TM regions.
Table 3. The results of logistic regression analysis of all variations using the features common to both TM and non-TM regions
All features (excluding position-
specific phylogenetic features)
SIFT only
a Position-specific phylogenetic
features only
All features
Disease Neutral Disease Neutral Disease Neutral Disease Neutral
Correct classification 221 167 257 173 247 217 249 219
Wrong classification 62 77 26 71 36 27 34 25
Total number of errors 139 (26.38%) 97 (18.41%) 63 (11.95%) 59 (11.20%)
Here, phylogenetic features refer to SIFT score, normalized site entropy and change in residue frequency.
aThe classification obtained by logistic regression analysis using only the SIFT score as the determining feature.
Table 4. Total error rate of misclassification of disease-causing and neutral
variation when each feature was assessed by itself in the logistic regression
analysis
Feature Error rate (%)
SIFT conservation score 18.41
Normalized site entropy 18.60
Change in residue frequency 19.92
BLOSUM62 score 27.70
GRANTHAM score 31.31
Change in volume 34.91
Change in hydrophobicity 37.95
Location of variation (i.e. TM or non-TM) 39.47
BLOSUM62 score (TM only) 22.53
PHAT (TM only) 24.90
Change in free energy of hydropathy (TM only) 27.27
Here, phylogenetic features refer to SIFT score, normalized site entropy and
change in residue frequency.
1718 Nucleic Acids Research, 2005, Vol. 33, No. 5From the above analyses, it is clear that position-speciﬁc
phylogenetic features that describe the conservation of amino
acid residue at a speciﬁc site are the best predictors for dis-
criminating disease-causing versus neutral variation. When
SIFT is used with its default settings, substitutions with SIFT
scores<0.05arepredictedtobeintolerantsubstitutions. Thisis
a very conservative cutoff. It can be seen that SIFT combined
with other features can be used to predict a higher number of
disease-causing mutations correctly by logistic regression ana-
lysis. Of the 283 disease-causing mutations, 213 are predicted
to be intolerant substitutions using the default SIFT setting.
However, logistic regression analysis using SIFT score in
conjunction with the other features classiﬁes 249 of them to
be disease-causing (Table 3). Using the regression coefﬁ-
cients for the model obtained from Table 3, 115 SNPs in
GPCRs from dbSNP are predicted to be deleterious. A list
of the 464 SNPs in GPCRs from dbSNP including the
features used in the logistic regression model can be down-
loaded from http://www.gersteinlab.org/proj/gpcrsnp. The log
odds ratio as calculated by Equation 1 is also included for each
SNP and the list is ordered according to the score. Thus, the
SNPs that are likely to be deleterious are shown in the top rows
of the table.
DISCUSSION
We have evaluated the disease-causing potential of non-
synonymous coding SNPs in GPCRs by assessing the nature
of the amino acid change using a variety of features, such as
BLOSUM62, GRANTHAM and PHAT substitution score
matrices, free energy change of hydropathy associated with
a substitution and changes in side-chain volume of residues
and hydrophobicity changes. In addition, we used three
different position-speciﬁc phylogenetic features, SIFT score,
normalized site entropy and change in residue frequency,
to evaluate the impact of an amino acid variation caused by
a nonsynonymous coding SNP.
Two control datasets were used to assess the relationship
between the above mentioned features and amino acid vari-
ations. The disease dataset has a preponderance of mutations
in transmembrane regions, whereas the neutral variations are
randomly distributed. Extreme values of BLOSUM62 can be
used to distinguish between disease-causing and neutral vari-
ation. BLOSUM62 scores < 1 are predominantly associated
with disease mutations and scores >1 are associated with neut-
ral variations. GRANTHAM scores cannot be used to clearly
differentiate between the two datasets. PHAT scores < 1 are
associated with disease mutations and scores >+2 are associ-
ated with neutral variations. In all the cases, the distribution of
dbSNPs in GPCRs is more similar to the neutral variations
than disease mutations. This indicates that most of the dbSNPs
inGPCRs areneutralvariationsandwill notseverely affectthe
function of the protein.
Logistic regression analyses of the predictions show that
the position-speciﬁc phylogenetic features are the best pre-
dictors of the effect of amino acid variation at a particular
position on the function of a protein. This is because these
Table 5. The results of logistic regression analysis of variations in TM regions
All features excluding position-
specific phylogenetic features
SIFT only Position-specific phylogenetic
features only
All features
Disease Neutral Disease Neutral Disease Neutral Disease Neutral
Correct classification 143 58 157 68 155 71 155 80
Wrong classification 21 31 7 21 9 18 9 9
Total number of errors 52 (20.55%) 28 (11.07%) 27 (10.67%) 18 (7.11%)
Here, phylogenetic features refer to SIFT score, normalized site entropy and change in residue frequency.
Table 6. The results of logistic regression analysis of variations in non-TM regions
All features excluding position-
specific phylogenetic features
SIFT only Position-specific phylogenetic
features only
All features
Disease Neutral Disease Neutral Disease Neutral Disease Neutral
Correct classification 77 117 100 114 93 142 94 143
Wrong classification 42 38 19 41 26 13 25 12
Total number of errors 80 (29.20%) 60 (21.90%) 39 (14.23%) 37 (13.50%)
Here, phylogenetic features refer to SIFT score, normalized site entropy and change in residue frequency.
Table 7. The error rate of misclassification of disease-causing and neutralvariations usingthe SIFT score,normalizedsite entropy and change in residue frequency
individually as predictors in the logistic regression analysis
Dataset SIFT score (%) Normalized
site entropy (%)
Change in residue
frequency (%)
Combining all three
features (%)
All variations 18.41 18.60 19.92 11.95
TM only 11.07 19.37 19.37 10.67
Non-TM only 21.90 19.71 20.07 14.23
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a speciﬁc position in a protein. Substitution scores, such as
BLOSUM62, are also phylogenetic features but are not
position-speciﬁc. Therefore, variations involving two amino
acids are given the same weight irrespective of their context
in the protein in substitution matrices. But features, such as
SIFT scores, change in residue frequency and normalized site
entropy describe the conservation of an amino acid at a
speciﬁc position in a sequence. Thus these position-
speciﬁc phylogenetic features, elucidated from multiple
sequence alignments, describe the strong evolutionary con-
straints placed on the speciﬁc amino acids necessary for the
protein’s function. Therefore, they are better discriminators
of disease-causing versus neutral variations. Hence, position-
speciﬁc phylogenetic features can be used as the most
powerful tools for the evaluation of SNPs and amino acid
variations.
Conservation indices based on MSA cannot be used for
species-speciﬁc sequences, i.e. those proteins that do not
have homologs in other organisms. In addition, some SIFT
predictions are labeled ‘low conﬁdence’ predictions. This
occurs either when there are few sequences homologous to
the query sequence or when the homologous sequences are
closely related and not very diverse. In such cases, the simple
physicochemical parameters of amino acids can be used to
get an estimate of the effect of an amino acid variation on
protein function. Thus, simple sequence features based on the
properties of amino acids can be useful to evaluate sequence
variations for those sequences which have no homologs
(species-speciﬁc SNPs), have few homologs or are not very
divergent, albeit with lower prediction accuracy.
Logistic regression analyses using all the features described
above indicate that 115 SNPs in GPCRs in dbSNP could be
deleterious to the protein. This subset of SNPs from dbSNP in
GPCRs are the best candidate SNPs for further genotyping and
in-depth experimental analyses to evaluate their effect on the
protein’s structure and function and thus their pathogenecity.
Based on our analysis of the assessment of the amino acid
variations using phylogenetic features in conjunction with
substitution matrix scores and other simple amino acid fea-
tures, it is clear that the majority of dbSNPs in GPCRs are
neutral variations.
In an analysis of variations in amino acid membrane trans-
porter genes, it was seen that the amino acid diversity in TM
regions was less than that of the extracellular and intracellular
loop regions (31). From a phylogenetic analysis of TM pro-
teins, Li and Tourasse (58) found that non-TM regions accu-
mulate twice the number of changes as their corresponding
TM regions. This study on the 7-TM GPCRs also shows sim-
ilar trends. It is of interest to note that the SNPs in GPCRS
from dbSNP are signiﬁcantly underrepresented in TM regions
compared with the loop regions. Similar observations were
reported by Lee et al. (10). This indicates that TM regions
are less variable than the soluble extra and intracellular loops.
Presumably, this is owing to the general sequence constraints
in membrane proteins.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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